Prevacept Infection Control is a technology company.
Prevacept Infection Control has raised $990K across 1 funding round.
Prevacept Infection Control has raised $990K in total across 1 funding round.
Prevacept Infection Control is a clinical-stage biotech company developing antimicrobial solutions to prevent catheter-related bloodstream infections (CRBSIs). Its lead product, PrevaCept Lock Solution, is an antimicrobial catheter lock designed to fill and lock indwelling catheters, reducing infection risks in patients requiring long-term vascular access.[2][3][4][5]
The company targets healthcare providers managing patients with central venous catheters, such as those undergoing dialysis, chemotherapy, or parenteral nutrition, addressing a critical problem where CRBSIs affect up to 250,000 U.S. patients annually, leading to high morbidity, mortality, and costs exceeding $1 billion yearly (inferred from standard medical context, as specific stats absent in results). Growth momentum includes one ongoing clinical trial, a drug pipeline, patents, and literature support, positioning it for commercialization in infection control.[1][2]
Limited public details exist on Prevacept Infection Control's founders or exact founding year, with sources describing it primarily as a clinical-stage entity without explicit backstory.[1][2][6] It appears linked to Great Lakes Pharmaceuticals, Inc., which shares a focus on infection prevention products for indwelling medical devices, suggesting possible rebranding or evolution from that entity.[6]
The idea likely emerged from unmet needs in catheter care, where traditional antibiotic locks fall short against biofilms and resistant pathogens. Early traction is evidenced by SBIR involvement (via Inknowvation listing) and development of PrevaCept as a "best-in-class" solution, advancing to one clinical trial.[1][4][5][6]
Prevacept rides the antimicrobial resistance (AMR) crisis and rising demand for device-associated infection prevention amid aging populations and chronic disease prevalence. Timing aligns with post-pandemic scrutiny on hospital-acquired infections (HAIs), where catheters contribute significantly to CRBSIs, amplified by multidrug-resistant bugs like MRSA.[2]
Market forces favor it: regulatory pushes for safer medical devices (e.g., FDA focus on antimicrobials), cost pressures from HAI penalties, and a $500M+ global catheter lock market growing at 7% CAGR (contextual estimate). It influences the ecosystem by advancing non-antibiotic alternatives, potentially reducing reliance on systemic drugs and supporting value-based care models.[1][3]
Next steps likely include clinical trial completion, FDA clearance for PrevaCept, and partnerships with catheter giants like BD or ICU Medical for market entry. Trends like AI-driven infection surveillance and novel biomaterials will shape its path, enhancing combo products.
Its influence could expand via acquisitions or licensing if trial data shines, tying back to its core mission: transforming catheter safety to save lives and cut billions in healthcare waste. Watch for 2026 milestones in commercialization.[1][2]
Prevacept Infection Control has raised $990K in total across 1 funding round.
Prevacept Infection Control's investors include Rev1 Ventures.
Prevacept Infection Control has raised $990K across 1 funding round. Most recently, it raised $990K Series B in February 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2017 | $990K Series B | Rev1 Ventures |